DHL Group has just announced an investment of $3.57bn over the next five years to enhance its logistics capabilities in the life sciences and healthcare sector. This is part of the Group’s “Strategy 2030” to reinforce DHL’s commitment to helping healthcare grow and serve patients effectively worldwide.
This announcement comes after DHL Group’s recent acquisition of CRYOPDP, a specialty courier focused on clinical trials, biopharma, and cell and gene therapies.
Under the investment, 25 per cent will be allocated to Asia Pacific as part of its plans to expand its global footprint to deliver integrated, faster and more reliable patient-centric logistics solutions in regions healthcare companies operate.
The investment will focus on enhancing high-quality infrastructure and technology across all logistics touchpoints. A significant part of it will be allocated to establishing new cross-divisional GPD-certified pharma hubs for multi-temperature shipment lanes to expand its cold chain capacity.
With the growing demand of critical areas such as clinical trials, biopharma, and cell and gene therapies, DHL is also investing in a specialised cooling infrastructure to accommodate low and ultra-low temperature ranges.
“Similar to DHL Group’s purpose of ‘Connecting people, improving lives’, our strategic investment in life sciences and healthcare is driven by our customers’ mission: delivering essential, often life-saving products to people in need,” said Oscar de Bok, CEO of DHL Supply Chain.
“We’re building high-quality, integrated logistics solutions that are as innovative and reliable as the products our customers create – ensuring that patients everywhere receive the right treatment, at the right time, with complete confidence.”
DHL Health Logistics will consolidate its life sciences and healthcare expertise under one unified umbrella to create a seamless end-to-end experience for customers, simplifying the management of complex, cross-border supply chains.
